Search

Displaying results 1891 - 1900 of 10000 in total
  1. Drug

    Betahistine

    go.drugbank.com/drugs/DB06698
    ApprovedInvestigational

    It is currently marketed in Canada by various companies, including Teva Pharmaceuticals. … It is thought to reduce symptoms through its actions on histamine receptors.

    Products: BETARIS 8 MG/ML ORAL DAMLA, 100 ML, BETARİS 8 MG/ML ORAL DAMLA, 30 ML
  2. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    [A258298,A258293] It was first approved by the FDA in May 2013 for the treatment of melanoma. … [L45583] Trametinib is currently approved to treat a variety of cancers with BRAF mutations, such as non-small cell lung cancer and thyroid cancer, as monotherapy or in combination with [dabrafenib], a

  3. Drug

    Solifenacin

    go.drugbank.com/drugs/DB01591
    ApprovedInvestigational

    [L7511] It has a long duration of action as it is usually taken once daily.[L7511] Solifenacin was granted FDA approval on 19 November 2004.[L7511] … Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.

    Categories: Drugs Used in Benign Prostatic HypertrophyProducts: SOLIFENACINA L M, SOLIFENACIN AL 5MG FTA
  4. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … Pegzilarginase is a recombinant, cobalt-substituted, and pegylated human arginase 1 enzyme therapy designed to address the underlying metabolic deficit in arginase 1 deficiency (ARG1-D).

    Synonyms: Optimised human arginase I, Co-ArgI-PEG modified human arginase I
  5. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    attacks, and hospitalization due to heart failure in adults with chronic kidney disease associated with type II diabetes mellitus. … [A236544] Eplerenone is more selective and has longer lasting effects.

  6. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing

  7. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    A potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.

  8. Drug

    Prezatide

    go.drugbank.com/drugs/DB11296
    Approved

    It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer are currently being investigated. … Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions [A19503]. Prezatide is used in cosmetic products for the skin and hair.

    Synonyms: Glycyl-L-histidyl-L-lysine
  9. Drug

    Brincidofovir

    go.drugbank.com/drugs/DB12151
    ApprovedInvestigational

    Brincidofovir is an oral antiviral drug used in the treatment of human smallpox infections. … It is a lipid conjugate pro-drug of the acyclic nucleotide analogue [cidofovir][L34404,A235725] - this lipid conjugate improves drug delivery to the target cells and significantly reduces the nephrotoxicity

  10. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [A7948] More than 99% of the drug compound is the R-enantiomer.[A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US.